Clovis Oncology, Inc. (CLVS) added to 47 new portfolios
Hess Corp. (HES) Shares Bought by National Pension Service
Investment Research Analysts Opinion: American Express Company (AXP), Urban Edge Properties (UE)
Simple Moving Average Analysis of Occidental Petroleum Corporation (OXY)
NA Increases Stake in Boston Scientific Corporation (NYSE:BSX)
Leerink Swann Reaffirms "Market Perform" Rating for Sucampo Pharmaceuticals (NASDAQ:SCMP)
13 January 2018, 11:53 | Hattie Nash
Over the past 50 days, Sucampo Pharmaceuticals, Inc. stock's -3.07% off of the high and 92.33% removed from the low. Recently, investment analysts covering the stock have updated the mean rating to 1.8. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Sunday, December 31st. Sucampo Pharmaceuticals, Inc. (SCMP) has declined 5.30% since January 12, 2017 and is downtrending. Maxim Group reaffirmed a buy rating and issued a $23.00 target price on shares of Sucampo Pharmaceuticals in a report on Thursday, November 2nd. They now have a $15.00 target price on the biopharmaceutical company's stock. Finally, Instinet began coverage on shares of Sucampo Pharmaceuticals in a research note on Tuesday, December 19th.
Ratings analysis reveals 67% of Sucampo Pharma's analysts are positive. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. The stock presently has an average rating of Buy and a consensus price target of $21.58. (NASDAQ:SCMP). New York State Teachers Retirement System has 0% invested in Sucampo Pharmaceuticals, Inc. The same analysts are predicting that the company shares will trade to $21.17 within the next 12-18 months. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. The stock of Sucampo Pharmaceuticals, Inc. The firm has a market capitalization of $846.46, a price-to-earnings ratio of -5.39, a P/E/G ratio of 5.07 and a beta of 1.45.
ATR value of the company was 1.51 and Relative Strength Index (RSI) was 81.71.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) reported its EPS in the last quarter as $0.27/Share beating the analyst estimate of $0.25/Share by a difference of $0.02.
In other news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Thursday, December 7th. They set a buy rating and a $14.00 price objective on the stock. The latest exchange of 12.93 Million shares is above its average trading activity of 10.48 Million shares.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP increased its position in shares of Sucampo Pharmaceuticals by 636.4% during the third quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company's stock valued at $513,000 after purchasing an additional 423 shares during the last quarter.
It is interesting to note that Sucampo Pharmaceuticals, Inc.
Medallion Financial (MFIN) Trading Up -3.5%
A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E. The indicator is non-directional meaning that it gauges trend strength whether the stock price is trending higher or lower.
Synergy Pharmaceuticals Inc. insiders have sold a net of -8,750,000 shares during the past three months, which implies that the company's top executives have been feeling bearish about the stock's outlook. Trexquant Investment LP purchased a new position in Sucampo Pharmaceuticals in the 3rd quarter worth about $122,000. Finally, Thrivent Financial For Lutherans raised its holdings in shares of Sucampo Pharmaceuticals by 11.3% in the second quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Sucampo Pharmaceuticals by 4.1% in the second quarter. Institutional investors own 65.29% of the company's stock.
TRADEMARK VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of worldwide copyright & trademark law. The original version of this report can be read at [[permalink]].
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally.
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The companyÂ's marketed product includes AMITIZA, a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC) in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension.
Reflections on the Current State of MannKind Corp. (MNKD)
The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.11). Following the acquisition, the vice president now directly owns 59,840 shares of the company's stock, valued at $150,796.80.
Shedding Some Light on the Numbers Behind MPLX LP (NYSE:MPLX)
The pipeline company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.02. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital.
Oprah was once Trump's pick for vice president
Each of us in this room is celebrated because of the stories that we tell, and this year we became the story. For her part, Winfrey, who has been in the TV business for almost 40 years, paused for dramatic effect.
Paychex Updates New Payroll Tax Withholding Tables
These tax changes are all scheduled to expire after 2025, though Republicans have said they want to make them permanent. Nonpartisan tax experts project that the law will bring lower taxes for the great majority of Americans, though not all.
White House refuses to comment on Mueller probe claims
She wasn't given the oath. "It's a Democrat hoax that was brought up as an excuse for losing an election", Trump said. That's perhaps ridiculous, a lot of people looked on that as being a very serious breach and it really was, ' he said.